14 results about "Albumin concentrations" patented technology

The invention relates to the technical field of medical treatment, and particularly discloses a compound prognosis model for cancer prognosis evaluation, a prognosis evaluation method and a calculator. The compound prognosis model is constructed based on inflammation burden related prognosis indexes ALNCR and TNM by stage combination; the creation method comprises the following steps: step 1, collecting albumin concentration, lymphocyte count, neutrophil count and C-reactive protein concentration data of a cancer patient; 2, calculating an ALNCR index according to a formula; 3, according to a clinical classic TNM staging system, the patients are divided into a TNM staging stage I, a TNM staging stage II, a TNM staging stage III or a TNM staging stage IV; 4, the ALNCR index obtained in the step 2 and the TNM staging result obtained in the step 3 are associated and integrated, and the individualized prognosis score of the ALNCR.TNM composite prognosis model is obtained through calculation. The method is suitable for clinical rapid application; high-risk patients can be accurately distinguished, a quantitative basis is provided for individualized treatment and follow-up visit strategy formulation, and excessive medical treatment or insufficient treatment is reduced.

The invention provides a bilirubin adsorbing material as well as a preparation method and application thereof, and belongs to the technical field of blood perfusion materials. The bilirubin adsorption material is mainly prepared from chitosan quaternary ammonium salt, microfibrillated cellulose, a surfactant and a cross-linking agent, wherein the surfactant is one or more of lauryl methacrylate, Span 80 and Span 85. The structure of the bilirubin adsorption material is that a hydrophilic polysaccharide chain is stabilized in a pore wall shell, and a hydrophobic chain of a surfactant is repelled and assembled to a pore wall core. When the bilirubin adsorption material adsorbs albumin-bilirubin, the adsorption effect is better than that of MFC / QCS frozen gel, and the adsorption capacity and the adsorption rate are enhanced along with the increase of the concentration of albumin.

The invention provides an intelligent delirium evaluation system for an intensive care unit, which solves the subjective limitation of a traditional delirium evaluation dependency scale through multi-modal data acquisition and mathematical model quantitative calculation, and specifically, acquires key data such as a brain tissue oxygenation index, a serum albumin concentration and a total plasma concentration in real time to obtain a delirium evaluation result. Through models such as a blood-brain barrier penetration coefficient and a free drug score, accurately calculating a core index of effective brain concentration, and dynamically adjusting an early warning threshold and a limb movement frequency in combination with ambient light intensity to divide risk levels; in the whole evaluation process, quantitative logic is constructed based on a pathophysiological mechanism, subjective judgment deviation of medical staff is avoided, and the problem of delirium intervention lag caused by missed judgment and misjudgment is effectively reduced.

The disclosure provides methods for improving sperm function and fertilizing ability for assisted reproduction techniques. The methods provided by the disclosure, in some embodiments entail sequential changes of temperature, bicarbonate concentration, albumin concentration and calcium ionophore.

The invention describes synthesis of a novel self-assembled organic nano sensor. The self-assembled organic nano sensor takes naphthalene sulfonate as a framework, and the size distribution is 40-2000 nanometers. The autofluorescence of the self-assembled organic nano sensor is very low, but the fluorescence activity is very high in the presence of albumin, so that the signal-to-noise ratio is very high. The generated fluorescence is in direct proportion to the concentration of albumin, and can be used for quantifying albumin in a sample. The self-assembled organic nano sensor can be used for linearly quantifying the albumin concentration in a range of 0.1 mg / L-3500mg / L. After the self-assembled organic nano sensor is introduced into a sample containing albumin for 5-10 seconds, the nano sensor can emit fluorescence. Through interaction with the self-assembled organic nano sensor, albumin in an aqueous solution shows stability of 20 days, and the stability is kept between-80 DEG C and + 95 DEG C.

The invention provides cat serum albumin as well as a separation method and application thereof, and relates to the technical field of genetic engineering. According to the invention, mutation is carried out on the cat serum albumin for the first time to obtain a beneficial mutation site, so that the cat serum albumin mutant which can be highly expressed in a pichia pastoris system is obtained. Moreover, the cat serum albumin mutant L94H disclosed by the invention not only has a good antioxidant effect, but also can remarkably improve the concentration of albumin in a cat body, and has a wide application prospect in the aspect of treating diseases such as cat hypoproteinemia, cirrhosis ascites and the like or relieving liver injury.

Serum-based topical compositions for use in companion animals and associated methods are described herein. The use of xenogeneic serum can decrease preparation time as well as decrease the risk of infections and incompatibilities between donor and recipient. Moreover, by lysing serum, additional growth factors and proteins are made bioavailable, enhancing antimicrobial and wound-healing properties. The use of bovine serum as a starting material further reduces albumin concentrations relative to autologous human or animal serum, minimizing antibiotic metabolism and enabling synergistic efficacy when co-administered with antimicrobial agents.

The present invention belongs to the technical field of genetic engineering, and discloses a feline serum albumin mutant, its expression method in CHO cells and its application. The present invention for the first time provides a feline serum albumin mutant Mut-FSA. By replacing the K at the 558th position at the end of the FSA amino acid sequence with R, the optimized Mut-FSA sequence is finally formed. Compared with the unmutated FSA, Mut-FSA can show more significant curative effect advantages in the treatment intervention of feline hypoproteinemia or acute blood loss. In addition, Mut-FSA can not only enable the serum albumin concentration of feline hypoproteinemia patients to be rapidly corrected within 24 hours after treatment intervention, but also effectively improve the serum albumin level and overall prognosis of the affected cats. The recombinant FSA prepared by the present invention can not only provide a more effective innovative therapy for feline hypoproteinemia or acute blood loss, but also has broad application prospects and industrialization value.

The invention discloses a construction method of a hepatocyte line with high albumin yield, a plasmid and a hepatocyte line. According to the invention, a human serum albumin gene and a YAP gene are inserted into a genome of HepG2 human liver tumor cells so as to obtain a liver cell line with high albumin yield; the nucleotide sequence of the human serum albumin gene is as shown in SEQ ID No: 1, and the nucleotide sequence of the YAP gene is as shown in SEQ ID No: 2. According to the HepcellPro-H cell line constructed by the invention, under a specific culture condition, the concentration of albumin in a cell culture supernatant detected by ELISA (Enzyme-Linked Immunosorbent Assay) is obviously increased compared with that of an unmodified wild type HepG2 cell, the production efficiency is obviously improved, the large-scale extraction period of albumin is shortened, and the potential tumorigenic risk of a viral vector is avoided.

The invention provides a method for recovering and preparing human serum albumin from waste obtained by extracting AT-III from a plasma component IV. The method comprises the following steps: dissolving a plasma component IV precipitate, and carrying out pressure filtration to obtain a pressure filtrate; carrying out filtration and ultrafiltration on the press filtrate to adjust the protein concentration, so as to obtain an ultrafiltration protein solution; carrying out AT-III affinity chromatography, and collecting a flow-through liquid; after the flow-through liquid is subjected to ultrafiltration protein regulation, albumin specific affinity gel chromatography is carried out, and eluent is collected; dialyzing the eluent with NaCl to obtain a human serum albumin stock solution; diluting the human serum albumin stock solution, adjusting the concentration of the human serum albumin, and adding a protective agent to obtain a human serum albumin diluted solution; performing pasteurization to obtain a human serum albumin semi-finished product; and sterilizing, sub-packaging and incubating the semi-finished product, and warehousing the qualified product. The method can achieve the purposes of secondary utilization of plasma resources and efficient recovery of high-purity human albumin, and solves the problems of resource waste, tedious procedures, high cost and difficulty in consideration of purity and recovery rate in the existing process.

The invention relates to the technical field of physical analysis for processing biological materials, in particular to a urinary albumin detection system and method based on a photonic crystal microarray chip, and the system comprises a spectrum fingerprint calibration module, a signal real-time deconstruction module, a dynamic feature extraction module and a protein concentration mapping module. According to the method, the steady-state reflection spectrum of the photonic crystal microarray is accurately calibrated and is endowed with a digital identity, fine-grained tracking of wavelength change is realized in detection, and then the maximum binding rate and the stable response amplitude are extracted in dynamic binding reaction, so that the deviation of single end-point detection is avoided through the acquisition of the dual characteristics, and the detection accuracy is improved. The result can reflect the binding rate and the concentration characteristic of the stable stage at the same time, on the basis, the accuracy and stability of urinary albumin concentration recognition are effectively improved in combination with a data-driven mapping analysis mode, the comprehensive analysis mode fuses dynamic process analysis and steady state characteristic extraction, and more reliable quantitative result output is achieved.

The present invention relates to the field of blood testing technology, and in particular to reagents and methods for detecting abnormal sample amounts. The present invention detects human albumin in a sample based on the fluorescent reaction between albumin and albumin blue. A reasonable acceptance range for emitted fluorescence is set for different sample amounts. If the acceptance range is exceeded, the sample amount added during the test is considered abnormal, indicating that the test result is invalid and requires retesting, or that the albumin concentration needs to be rechecked. Experiments have shown that the method provided by the present invention is accurate and reliable, and can effectively reduce the risk of false positives during testing.

The present invention provides feline serum albumin, its isolation method, and applications, relating to the field of genetic engineering technology. This invention, for the first time, mutates feline serum albumin to obtain beneficial mutation sites, thereby producing a feline serum albumin mutant that can be highly expressed in a Pichia pastoris system. Furthermore, the feline serum albumin mutant L94H not only exhibits excellent antioxidant effects but also significantly increases albumin concentration in cats, offering promising applications in treating feline hypoproteinemia, cirrhosis, ascites, and other conditions, or alleviating liver damage.

The application discloses an organic small molecule which can be activated by alkaline phosphatase and visible light, and a preparation method and application thereof. The structural formula of the organic small molecule is shown as formula I. The organic small molecule and cis-trans isomers thereof exist in a stable cis or trans configuration under dark conditions and have no cytotoxicity. Under visible light irradiation, the organic small molecule undergoes cis-trans isomerization, and the isomerization efficiency is regulated by the concentration of serum albumin in the environment. Based on this, the good biocompatibility of visible light and the wide existence of albumin in vivo can be used as a double regulation means, so that the organic small molecule has no toxic side effects under high serum albumin physiological conditions. In a tumor cell environment, through visible light irradiation and albumin concentration removal, the organic small molecule is in a trans configuration, and through alkaline phosphatase reaction, the organic small molecule has a high tumor cell killing ability, achieves time and space control of drug activity, and has application prospects in on-demand precise treatment of tumors.